STIM

BEARISH

$1.42 Live

Neuronetics, Inc. · NASDAQ

Target $4.33 (+205.2%)

$0.8 52W Range $4.85

STIM Neuronetics, Inc. - Fundamental Analysis

BEARISH

Console Chart News

STIM Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Medical Devices

Current Price Live

$1.42

Analyst Target

$4.33

+205.2% Upside

52W High

$4.85

52W Low

$0.8

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 20, 2026

Market cap

$98.8M

P/E

N/A

ROE

-134.9%

Profit margin

-26.1%

Debt/Equity

3.44

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

STIM exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a high Debt/Equity ratio of 3.44. While the company shows impressive top-line revenue growth of 85.70%, this is completely offset by a devastating ROE of -134.86% and consistent net losses. The combination of a 0/100 technical trend, bearish insider selling by the CEO and CFO, and a 62.2% one-year price decline suggests a high-risk profile. Despite bullish analyst targets, the deterministic health metrics indicate a company struggling for solvency.

Key Strengths

Strong YoY revenue growth of 85.70%

Low Price-to-Sales ratio (0.66) suggesting potential undervaluation of revenue

Healthy Current Ratio (2.02) providing short-term liquidity

Positive Gross Margin of 48.75%

Significant upside gap to analyst target price ($4.33)

Key Risks

Critical financial health (Piotroski F-Score 1/9)

High leverage with Debt/Equity at 3.44

Severe negative ROE (-134.86%) indicating inefficient capital use

Consistent earnings misses with an average surprise of -28.91% over the last 4 quarters

Strong bearish momentum with a 5-year price decline of 87.2%

AI Fair Value Estimate

Based on comprehensive analysis

$1.3

-8.5% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

High Risk / Speculative

Key drivers: Extreme financial instability, Bearish insider sentiment, Strong revenue growth vs. worsening losses

Confidence

90%

Value

40/100

Trades at a discount to sales but a premium to book value without earnings support.

Positives

Low P/S ratio

Watchpoints

High P/B ratio (4.38) for a non-profitable firm
No P/E or Graham Number due to lack of earnings

Future

45/100

Growth is present in sales but not translating to the bottom line.

Positives

Rapid revenue expansion (85%+)

Watchpoints

Negative EPS growth (-150% YoY)
High cash burn implied by margins

Past

10/100

Long-term trend is aggressively bearish.

Positives

No standout positives identified.

Watchpoints

Catastrophic 5-year return (-87.2%)
Consistent failure to meet earnings estimates

Health

10/100

Deterministic health scores indicate extreme weakness and potential distress.

Positives

Current ratio above 2.0

Watchpoints

Piotroski F-Score of 1/9
Debt/Equity of 3.44

Dividend

0/100

Non-dividend paying growth/distress stock.

Positives

No standout positives identified.

Watchpoints

No dividend history

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$1.42

Analyst Target

$4.33

Upside/Downside

+205.2%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for STIM and closest competitors.

Updated 2026-04-17

Company	5Y	3Y	1Y	6M	1M	1W
STIM Neuronetics, Inc. Primary	-87.2%	-31.4%	-62.2%	-47.2%	+5.2%	+5.2%
KZIA Kazia Therapeutics Limited Peer	-98.5%	-84.8%	+141.6%	+26.4%	+8.8%	+20.2%
IMDX Insight Molecular Diagnostics Inc. Peer	-97.0%	-53.0%	+9.3%	-18.5%	-39.6%	-15.7%
MXCT MaxCyte, Inc. Peer	-94.8%	-83.5%	-66.1%	-46.6%	+8.7%	+24.1%
BDSX Biodesix, Inc. Peer	-97.8%	-75.2%	-34.9%	+31.6%	+72.1%	+49.0%

STI

Neuronetics, Inc.

Primary

-87.2%

-31.4%

-62.2%

-47.2%

+5.2%

KZI

Kazia Therapeutics Limited

Peer

-98.5%

-84.8%

+141.6%

+26.4%

+8.8%

+20.2%

IMD

Insight Molecular Diagnostics Inc.

Peer

-97.0%

-53.0%

+9.3%

-18.5%

-39.6%

-15.7%

MXC

MaxCyte, Inc.

Peer

-94.8%

-83.5%

-66.1%

-46.6%

+8.7%

+24.1%

BDS

Biodesix, Inc.

Peer

-97.8%

-75.2%

-34.9%

+31.6%

+72.1%

+49.0%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-4.44

N/A

4.38

0.66

1.1

-5.95

$98.8M

Profitability

Profit margins and return metrics

Profit Margin -26.15%

Operating Margin -11.11%

Gross Margin 48.75%

ROE -134.86%

ROA -13.73%

Growth

Revenue and earnings growth rates

Revenue Growth +85.7%

Earnings Growth N/A

Q/Q Revenue Growth +85.73%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

3.44

High debt

Current Ratio

2.02

Strong

Quick Ratio

1.47

Good

Cash/Share

$0.41

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.0B

Gross Margin

52.0%

Op. Margin

-12.1%

Net Margin

-17.1%

Total Assets

$0.1B

Liabilities

$0.1B

Equity

$0.0B

Debt/Equity

5.15x

Operating CF

$0.0B

CapEx

$-0.0B

Free Cash Flow

$0.0B

FCF Yield

76%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-05

$N/A

2026-03-17

$-0.1

+9.1% surprise

2025-11-04

$-0.13

-8.3% surprise

2025-08-05

$-0.15

-87.5% surprise

Healthcare Sector Comparison

Comparing STIM against 470 companies in the Healthcare sector (26 bullish, 143 neutral, 301 bearish)

Return on Equity (ROE)

-134.86%

This Stock

-97.91%

Sector Avg

+37.7% (Excellent)

Profit Margin

-26.15%

This Stock

-16.16%

Sector Avg

+61.8% (Superior)

Debt to Equity

3.44

This Stock

3.0

Sector Avg

+14.7% (Higher)

Revenue Growth

85.7%

This Stock

142.9%

Sector Avg

-40.0% (Slower)

Current Ratio

2.02

This Stock

4.65

Sector Avg

-56.6% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
STIM Neuronetics, Inc.	BEARISH	$98.8M	-	-134.9%	-26.1%	$1.42
KZIA Kazia Therapeutics Limited	NEUTRAL	$100.79M	-	-106.9%	-%	$8.82	Compare
IMDX Insight Molecular Diagnostics Inc.	BEARISH	$101.97M	-	-%	-%	$3.17	Compare
MXCT MaxCyte, Inc.	BEARISH	$94.19M	-	-23.6%	-135.1%	$0.88	Compare
BDSX Biodesix, Inc.	BEARISH	$93.92M	-	-302.6%	-49.3%	$11.74	Compare

STIM Neuronetics, Inc.

BEARISH

Mkt Cap

$99M

P/E

ROE

-134.9%

Price

$1.42

Compare with STIM

Compare with STIM

Compare with STIM

Compare with STIM

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-03-30	CHERNETT JOREY	Beneficial Owner of more than 10% of a Class of Security	Purchase	385,442	$481,802
2026-03-27	CHERNETT JOREY	Beneficial Owner of more than 10% of a Class of Security	Purchase	500,000	$675,000
2026-03-26	CHERNETT JOREY	Beneficial Owner of more than 10% of a Class of Security	Purchase	150,000	$211,000
2026-03-23	REUVERS DANIEL L	Chief Executive Officer	Stock Award	1,500,000	-
2026-03-20	CHERNETT JOREY	Beneficial Owner of more than 10% of a Class of Security	Purchase	169,472	$238,956
2026-03-19	SULLIVAN KEITH J	Former	Sale	46,289	$62,027
2026-03-19	MACAN WILLIAM ANDREW	Officer	Sale	16,005	$21,447
2026-03-19	PFANSTIEL STEVEN	Chief Financial Officer	Sale	16,431	$22,018
2026-03-19	CHERNETT JOREY	Beneficial Owner of more than 10% of a Class of Security	Purchase	1,057,400	$1,418,490
2026-03-17	SULLIVAN KEITH J	Chief Executive Officer	Stock Award	112,500	-
2026-03-17	MACAN WILLIAM ANDREW	Officer	Stock Award	33,750	-
2026-03-17	PFANSTIEL STEVEN	Chief Financial Officer	Stock Award	25,000	-
2026-03-17	CHERNETT JOREY	Beneficial Owner of more than 10% of a Class of Security	Purchase	531,000	$615,960
2026-03-04	MACAN WILLIAM ANDREW	Officer	Sale	609	$816
2026-02-26	SULLIVAN KEITH J	Chief Executive Officer	Sale	8,452	$11,410

CHERNETT JOREY

Beneficial Owner of more than 10% of a Class of Security

Buy

2026-03-30

385,442 shares · $481,802

CHERNETT JOREY

Beneficial Owner of more than 10% of a Class of Security

Buy

2026-03-27

500,000 shares · $675,000

CHERNETT JOREY

Beneficial Owner of more than 10% of a Class of Security

Buy

2026-03-26

150,000 shares · $211,000

REUVERS DANIEL L

Chief Executive Officer

Stock Award

2026-03-23

1,500,000 shares

CHERNETT JOREY

Beneficial Owner of more than 10% of a Class of Security

Buy

2026-03-20

169,472 shares · $238,956

SULLIVAN KEITH J

Former

Sell

2026-03-19

46,289 shares · $62,027

MACAN WILLIAM ANDREW

Officer

Sell

2026-03-19

16,005 shares · $21,447

PFANSTIEL STEVEN

Chief Financial Officer

Sell

2026-03-19

16,431 shares · $22,018

CHERNETT JOREY

Beneficial Owner of more than 10% of a Class of Security

Buy

2026-03-19

1,057,400 shares · $1,418,490

SULLIVAN KEITH J

Chief Executive Officer

Stock Award

2026-03-17

112,500 shares

MACAN WILLIAM ANDREW

Officer

Stock Award

2026-03-17

33,750 shares

PFANSTIEL STEVEN

Chief Financial Officer

Stock Award

2026-03-17

25,000 shares

CHERNETT JOREY

Beneficial Owner of more than 10% of a Class of Security

Buy

2026-03-17

531,000 shares · $615,960

MACAN WILLIAM ANDREW

Officer

Sell

2026-03-04

609 shares · $816

SULLIVAN KEITH J

Chief Executive Officer

Sell

2026-02-26

8,452 shares · $11,410

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

DEF 14A

2026-04-09

STIM filed a definitive proxy statement (DEF 14A) on April 9, 2026, providing shareholders with necessary information to vote on corporate matters.

8-K

2026-04-06

STIM filed an 8-K on April 6, 2026, likely to announce its first-quarter financial results.

8-K

2026-03-17

STIM filed a current report on March 17, 2026, likely announcing its annual financial results.

10-K

2026-03-17

STIM filed its annual 10-K report on March 17, 2026, which includes detailed sections on its business operations, risk factors, and management's discussion and analysis of financial condition. Specific financial highlights and risk details were not provided in the available excerpts.

8-K

2026-03-02

STIM likely filed this 8-K to announce its annual financial results for the fiscal year ended December 31, 2025.

8-K

2026-02-25

STIM filed an 8-K on February 25, 2026, likely to report its fourth-quarter and full-year financial results.

8-K

2026-02-10

STIM filed an 8-K on February 10, 2026, likely to announce its fourth quarter and full-year financial results.

8-K

2026-01-22

STIM filed an 8-K on January 22, 2026, likely to announce its fourth-quarter or full-year financial results.

8-K

2026-01-06

10-Q

2025-11-04

STIM filed its quarterly 10-Q report on November 4, 2025. The provided excerpts do not contain specific financial highlights or detailed risk factors beyond a reference to Item 1A.

8-K

2025-11-04

10-Q

2025-08-05

8-K

2025-08-05

8-K

2025-07-15

8-K

2025-05-28

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

BUY

3 analysts

Canaccord Genuity

2026-03-19

Maintains

Buy Buy

Past News Coverage

Recent headlines mentioning STIM from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

STIM

STIM Neuronetics, Inc. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!